Skip to content

Study · Animal study (in vivo) · mouse · 2017

5 results

Zonulin transgenic mice show altered gut permeability and increased morbidity/mortality in the DSS colitis model.

Sturgeon C, Lan J, Fasano A

Annals of the New York Academy of Sciences19 Apr 2017Cited by 65 (Europe PMC)

PMID28423466 (opens in a new tab)PMCIDPMC5479715 (opens in a new tab)DOI10.1111/nyas.13343 (opens in a new tab)PepBankPUB-28423466
Source linkPubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In zonulin transgenic mice, AT1001 prevented the DSS-induced increase in intestinal permeability in vivo.

    In plain wordsIn mice, AT1001 prevented the rise in intestinal permeability caused by DSS compared with DSS without AT1001.

    Peptide
    Larazotide
    Outcome
    DecreaseIntestinal permeability in vivo
    Study

    mousen: not reported in source

    Zonulin transgenic Hp2 mice with DSS colitis
    Comparator
    DSS without AT1001
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    Dose not stated · drinking waterAs given in this study (mouse).

    Source sentences

    Summary
    Treatment with AT1001 prevented the DSS-induced increased IP both in vivo and ex vivo without changing zonulin gene expression and completely reverted morbidity and mortality in Ztm.
    2 context sentences
    Summary · context
    Zonulin transgenic Hp2 mice (Ztm) were subjected to dextran sodium sulfate (DSS) treatment for 7 days, followed by 4-7 days' recovery and compared to C57Bl/6 (wild-type (WT)) mice.
    Summary · context
    To mechanistically link zonulin-dependent impairment of small intestinal barrier function with clinical outcome, Ztm were treated with the zonulin inhibitor AT1001 added to drinking water in addition to DSS.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In zonulin transgenic mice, AT1001 prevented the DSS-induced increase in intestinal permeability measured ex vivo.

    In plain wordsIn mice, AT1001 prevented the rise in intestinal permeability measured in removed tissue compared with DSS without AT1001.

    Peptide
    Larazotide
    Outcome
    DecreaseIntestinal permeability ex vivo
    Study

    mousen: not reported in source

    Zonulin transgenic Hp2 mice with DSS colitis
    Comparator
    DSS without AT1001
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    Dose not stated · drinking waterAs given in this study (mouse).

    Source sentences

    Summary
    Treatment with AT1001 prevented the DSS-induced increased IP both in vivo and ex vivo without changing zonulin gene expression and completely reverted morbidity and mortality in Ztm.
    2 context sentences
    Summary · context
    Zonulin transgenic Hp2 mice (Ztm) were subjected to dextran sodium sulfate (DSS) treatment for 7 days, followed by 4-7 days' recovery and compared to C57Bl/6 (wild-type (WT)) mice.
    Summary · context
    To mechanistically link zonulin-dependent impairment of small intestinal barrier function with clinical outcome, Ztm were treated with the zonulin inhibitor AT1001 added to drinking water in addition to DSS.
  3. 03AnimalAnimal study (in vivo)Mechanism

    In zonulin transgenic mice with DSS colitis, AT1001 did not change zonulin gene expression.

    In plain wordsIn mice with DSS colitis, AT1001 did not change zonulin gene expression compared with DSS without AT1001.

    Peptide
    Larazotide
    Outcome
    No significant changeZonulin gene expression
    Study

    mousen: not reported in source

    Zonulin transgenic Hp2 mice with DSS colitis
    Comparator
    DSS without AT1001
    Outcome group
    Receptor activity and mechanism · Gastrointestinal
    Studied dose
    Dose not stated · drinking waterAs given in this study (mouse).

    Source sentences

    Summary
    Treatment with AT1001 prevented the DSS-induced increased IP both in vivo and ex vivo without changing zonulin gene expression and completely reverted morbidity and mortality in Ztm.
    2 context sentences
    Summary · context
    Zonulin transgenic Hp2 mice (Ztm) were subjected to dextran sodium sulfate (DSS) treatment for 7 days, followed by 4-7 days' recovery and compared to C57Bl/6 (wild-type (WT)) mice.
    Summary · context
    To mechanistically link zonulin-dependent impairment of small intestinal barrier function with clinical outcome, Ztm were treated with the zonulin inhibitor AT1001 added to drinking water in addition to DSS.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In zonulin transgenic mice, AT1001 completely reversed DSS-associated morbidity.

    In plain wordsIn mice, AT1001 completely reversed DSS-associated illness compared with DSS without AT1001.

    Peptide
    Larazotide
    Outcome
    DecreaseMorbidity
    Study

    mousen: not reported in source

    Zonulin transgenic Hp2 mice with DSS colitis
    Comparator
    DSS without AT1001
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    Dose not stated · drinking waterAs given in this study (mouse).

    Source sentences

    Summary
    Treatment with AT1001 prevented the DSS-induced increased IP both in vivo and ex vivo without changing zonulin gene expression and completely reverted morbidity and mortality in Ztm.
    2 context sentences
    Summary · context
    Zonulin transgenic Hp2 mice (Ztm) were subjected to dextran sodium sulfate (DSS) treatment for 7 days, followed by 4-7 days' recovery and compared to C57Bl/6 (wild-type (WT)) mice.
    Summary · context
    To mechanistically link zonulin-dependent impairment of small intestinal barrier function with clinical outcome, Ztm were treated with the zonulin inhibitor AT1001 added to drinking water in addition to DSS.
  5. 05AnimalAnimal study (in vivo)Safety outcome

    In zonulin transgenic mice, AT1001 completely reversed DSS-associated mortality.

    In plain wordsIn mice, AT1001 completely reversed DSS-associated mortality compared with DSS without AT1001.

    Peptide
    Larazotide
    Outcome
    DecreaseMortality
    Study

    mousen: not reported in source

    Zonulin transgenic Hp2 mice with DSS colitis
    Comparator
    DSS without AT1001
    Outcome group
    Mortality · Whole body
    Studied dose
    Dose not stated · drinking waterAs given in this study (mouse).

    Source sentences

    Summary
    Treatment with AT1001 prevented the DSS-induced increased IP both in vivo and ex vivo without changing zonulin gene expression and completely reverted morbidity and mortality in Ztm.
    2 context sentences
    Summary · context
    Zonulin transgenic Hp2 mice (Ztm) were subjected to dextran sodium sulfate (DSS) treatment for 7 days, followed by 4-7 days' recovery and compared to C57Bl/6 (wild-type (WT)) mice.
    Summary · context
    To mechanistically link zonulin-dependent impairment of small intestinal barrier function with clinical outcome, Ztm were treated with the zonulin inhibitor AT1001 added to drinking water in addition to DSS.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.